Elite Pharmaceuticals, Inc.
ELTP
$0.53
$0.010.95%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 72.67% | 58.70% | 48.42% | 47.93% | 73.47% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 72.67% | 58.70% | 48.42% | 47.93% | 73.47% |
| Cost of Revenue | 47.89% | 28.18% | 45.23% | 52.46% | 83.23% |
| Gross Profit | 103.30% | 95.60% | 52.09% | 42.57% | 62.75% |
| SG&A Expenses | 47.83% | 39.41% | 26.34% | 62.82% | 60.54% |
| Depreciation & Amortization | 3.94% | 12.20% | 22.36% | 24.87% | 20.51% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 39.89% | 24.37% | 37.10% | 43.29% | 58.72% |
| Operating Income | 199.57% | 199.13% | 96.54% | 74.78% | 170.94% |
| Income Before Tax | 450.63% | -10,483.69% | -111.25% | -626.22% | -1,044.24% |
| Income Tax Expenses | 2,658.43% | 147.79% | 121.70% | 103.66% | 97.75% |
| Earnings from Continuing Operations | 317.96% | -155.23% | -121.46% | -215.64% | -135.85% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 317.96% | -155.23% | -121.46% | -215.64% | -135.85% |
| EBIT | 199.57% | 199.13% | 96.54% | 74.78% | 170.94% |
| EBITDA | 180.81% | 180.38% | 88.33% | 66.41% | 141.21% |
| EPS Basic | 328.07% | -152.33% | -120.20% | -208.50% | -132.57% |
| Normalized Basic EPS | 396.00% | 109.09% | 212.50% | -339.13% | -- |
| EPS Diluted | 112.36% | -228.07% | -133.61% | -294.12% | -171.77% |
| Normalized Diluted EPS | 386.00% | 109.09% | 212.50% | -339.13% | -- |
| Average Basic Shares Outstanding | 2.56% | 3.82% | 5.21% | 4.12% | 2.82% |
| Average Diluted Shares Outstanding | 3.41% | 2.86% | 4.60% | 4.29% | 3.48% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |